ABCC5 and prostate cancer: In CPGEA (p = 0.0091), MSKCC (p = 0.041), and TCGA-PRAD (p < 0.0001), we found shorter progression-free survival (RFS) times in prostate cancer patients with high ABCC5 expression than those with low expression (Figure 2E-G).